IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Update for IXCHIQ Chikungunya vaccine.

Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicated in all individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease.

This action follows very rare fatal reactions, and other serious adverse reactions reported globally last year. In addition, the CHM have advised that the IXCHIQ vaccine should be given no later than 30 days prior to travel.

Further information and advice can be found in the Drug Safety Update.